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Abstract: Epicardial adipose tissue (EAT) is derived from splanchnic mesoderm, localized anatomically
between the myocardium and pericardial visceral layer, and surrounds the coronary arteries. Being
a metabolically active organ, EAT secretes numerous cytokines, which moderate cardiovascular
morphology and function. Through its paracrine and vasocrine secretions, EAT may play a prominent
role in modulating cardiac function. EAT protects the heart in normal physiological conditions
by secreting a variety of adipokines with anti-atherosclerotic properties, and in contrast, secretes
inflammatory molecules in pathologic conditions that may play a dynamic role in the pathogenesis
of cardiovascular diseases by promoting atherosclerosis. Considerable research has been focused
on comparing the anatomical and biochemical features of EAT in healthy people, and a variety of
disease conditions such as cardiovascular diseases and renal diseases. The global cardiovascular
morbidity and mortality in renal disease are high, and there is a paucity of concrete evidence and
societal guidelines to detect early cardiovascular disease (CVD) in this group of patients. Here we
performed a clinical review on the existing evidence and knowledge on EAT in patients with renal
disease, to evaluate its application as a reliable, early, noninvasive biomarker and indicator for CVD,
and to assess its significance in cardiovascular risk stratification.
Keywords: Epicardial Adipose Tissue; Renal disease; Chronic Kidney disease; Inflammation;
Coronary artery calcification; Cardiovascular risk
1. Introduction
Different fat compartments around the heart (see Figure 1 [1–4]) have different embryological
origins and functional activity [5]. Epicardial adipose tissue (EAT), a component of the visceral
fat compartment, is located between the myocardium and the pericardial visceral layer, without
any separating fascia or other tissue; EAT is directly in contact with the myocardium and coronary
vessels [5] (see Figure 1 [1–4]). It covers 80% of the cardiac surface and accounts for approximately 20%
of the total cardiac weight [6]. EAT is a derivative of splanchnopleuric mesoderm and is comprised of
different cell types including adipocytes, nervous and nodal tissue, inflammatory, stromal, and immune
cells [7].
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Figure 1. Physiological and pathological functions of epicardial adipose tissue (EAT). Schematic 
diagram illustrating the anatomical location of EAT, different modalities used to measure it and its 
various physiological and pathological functions. IL, interleukin; INOS, inducible nitric oxide 
synthase; MCP-1, monocyte chemoattractant protein-1; PAI-1, plasminogen activator inhibitor-1; 
TNF-α, tumor necrosis factor α; VEGF, vascular endothelial growth factor. 
Like other white adipose tissues, EAT has an endocrine function with the ability to secrete 
hormones and inflammatory cytokines [5,7]. Evidence suggests that EAT plays a multifaceted role in 
essential physiological functions of the heart such as regulation of local fatty acid homeostasis, 
providing a local energy source, angiogenesis, protecting cardiomyocytes from lipotoxicity by 
reducing the influx of high free fatty acids, coronary artery remodeling, safeguarding the heart 
against hypothermia, and buffering of the coronary arteries against torsion induced by myocardial 
contraction and arterial pulse wave [4,8,9] (see Figure 1 [1–4]). Furthermore, the adipocytokines 
secreted from EAT such as adiponectin, apelin, adrenomedullin, leptin, and omentin have 
cardioprotective effects [3]. The expression and secretion of proinflammatory cytokines, such as 
interleukin-6 (IL-6), interleukin-1β (IL-1β), monocyte chemoattractant protein 1 (MCP-1), and tumor 
necrosis factor-α (TNF-α), are higher in the EAT of patients with coronary heart disease than in 
subcutaneous fat of the same individuals, and the pathological enlargement of EAT correlates 
significantly with increased cardiovascular disease (CVD) risk [10]. The importance of EAT 
concerning the inflammatory burden in CVD is established [11] with the paracrine and vasocrine 
secretion of pro-inflammatory adipokines. Adipokines are thought to directly contribute to the 
myocardial inflammation, left ventricular hypertrophy (LVH), coronary artery disease (CAD), and 
myocardial dysfunction through the generation of local reactive oxygen species, creating a pro-
atherogenic state, and as a direct local effect of inflammatory cytokines [10,12].  
Chronic kidney disease (CKD) is one of the leading causes of mortality and morbidity across the 
globe with its incidence growing exponentially. According to different estimates, CKD has a 
consistent estimated global prevalence of about 11 to 13% [13]. As per the World Health 
Organization’s (WHO) global health estimates in 2016, kidney disease was the 12th most common 
cause of death worldwide, accounting for 1.18 million deaths [14]. CKD is a significant risk factor for 
CVD and risk increases with increased severity of the CKD. A meta-analysis of the urine albumin-to-
creatinine ratio (ACR) data from 105,872 participants and urine protein dipstick measurement data 
from 1,128,310 participants, found that eGFR (estimated glomerular filtration rate) and albuminuria 
were associated with all-cause and cardiovascular mortality independently of each other and 
traditional cardiovascular risk factors [15]. In this study, two-fold higher mortality risk was observed 
Figure 1. Physiological and pathological f ctio s of epicardial adipose tissue (EAT). Schematic
diagram illustrating the anatomical location of EAT, different modalities used to measure it and its
various physiological and pathological functions. IL, interleukin; INOS, inducible nitric oxide synthase;
MCP-1, monocyte chemoattractant protein-1; PAI-1, plasminogen activator inhibitor-1; TNF-α, tumor
necrosis factor α; VEGF, vascular endothelial growth factor.
Like other white adipose tissues, EAT has an endocrine function with the ability to secrete
hormones and inflammatory cytokines [5,7]. Evidence suggests that EAT plays a multifaceted role
in essential physiological functions of the heart such as regulation of local fatty acid homeostasis,
providing a local e ergy source, angiogenesis, protecting cardiomyocytes from lipotoxicity by reducing
the influx of hig free fatty acids, c ronary artery r modeli g, safeguarding the heart against
hypothermia, and buffering of the coronary arteries against torsion induced by myocardial contraction
and arterial pulse wave [4,8,9] (see Figure 1 [1–4]). Furthermore, the adipocytokines secreted from EAT
such as adiponectin, apelin, adrenomedullin, leptin, and omentin have cardioprotective effects [3].
The expression and secretion of proinflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β
(IL-1β), monocyte chemoattractant protein 1 (MCP-1), and tumor necrosis factor-α (TNF-α), are higher
in the EAT of patients with coronary heart disease than in subcutaneous fat of the same individuals,
and the pathological enlargement of EAT correlates significantly with increased cardiovascular disease
(CVD) risk [10]. The importance of EAT co cerning the infl mmatory burden in CVD is established [11]
with the p acrine nd vasocrine s cretion of pro-inflammatory adipokines. Adipokines are thought
to directly contribute to the myocardial inflammation, left ventricular hypertrophy (LVH), coronary
artery disease (CAD), and myocardial dysfunction through the generation of local reactive oxygen
species, creating a pro-atherogenic state, and as a direct local effect of inflammatory cytokines [10,12].
Chronic kidney disease (CKD) is one of the leading causes of mortality and morbidity across the
globe with its incidence growing exponentially. According to different estimates, CKD has a consistent
estimated global prevalence of about 11 to 13% [13]. As per the World Health Organization’s (WHO)
global health estimates in 2016, kidney disease was the 12th most common cause of death worldwide,
accounting for 1.18 million deaths [14]. CKD is a sig ificant risk factor for CVD and risk increases with
increased severity of the CKD. A meta-analysis of the urine albumin-to-creatinine r tio (ACR) data from
105,872 participants and urine protei dipstick measurement data from 1,128,310 participants, found
that eGFR (estimated glomerular filtration rate) and albuminuria were associated with all-cause and
cardiovascular mortality independently of each other and traditional cardiovascular risk factors [15]. In
this study, two-fold higher mortality risk was observed in patients with eGFR 30−45 mL/min/1.73 m2
as compared to patients with optimal eGFR levels. Similarly, patients with an ACR of approximately
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100 mg/g were found to be at two-fold higher risk of mortality as compared to those with optimal
ACR levels (5 mg/g) [15].
Considerable evidence indicates a significant association between EAT thickness and the incidence
of CVD events in CKD patients. This review summarizes the current knowledge on EAT concerning
renal disease, different non-pharmacological and pharmacological modalities to reduce EAT and
evaluate it as a reliable, early, new parameter for CVD risk stratification. A literature search was
carried out in PubMed and Google Scholar using the various combinations of following keywords:
epicardial adipose tissue, chronic kidney disease, end-stage renal disease, renal failure, coronary
calcification, and cardiovascular disease. Appropriate articles/abstracts (published in the English
language) identified in the search were included in the manuscript.
2. Pathological Roles of EAT
Evidence indicates the involvement of cross-talk between EAT and the myocardium in cardiac
disease pathogenesis [4]. It is revealed that in patients with essential hypertension and normal LV
systolic function, EAT thickness is associated with left ventricular (LV) diastolic dysfunction and
increased left atrial volume, independent of blood pressure, LV mass, and other risk factors [16].
In patients with preserved ejection fraction, EAT accumulation might contribute to the initial
development of LV systolic dysfunction [17]. Moreover, epicardial fat volume (EFV) is identified
as an independent predictor of a rapid increase in lipid-rich plaque volume [18], and acute coronary
syndrome in patients with CAD [19].
EAT has been suggested to play a pivotal role in the initiation of atherosclerosis, mediating
the secretion of bioactive molecules such as free fatty acids, and a variety of other cytokines or
chemokines [1] (see Figure 1 [1–4]). By the expression profile analysis of various inflammatory
molecules in EAT and subcutaneous fat isolates from patients undergoing coronary artery bypass
grafting (CABG), Mazurek et al. showed significantly higher levels of chemokine MCP-1, and several
inflammatory cytokines (IL-1β, IL-6, IL-6sR, and TNF-α) in EAT [7]. Furthermore, secretion of
pro-inflammatory cytokines such as TNF-α, MCP-1, IL-1β, IL-6, and resistin amplified by the size
changes in epicardial adipocytes along with the increased number of macrophages and T lymphocytes
ultimately enhance atherogenesis [20,21].
As EAT is in direct contact with the adventitia of coronary arteries, adipocytokines from
peri-adventitial EAT may pass through the coronary wall by diffusion and might promote the
proliferation of vasa vasorum [22]. Corroborating this, it has been shown in the in vivo studies
on pigs that the increase in intimal thickness and coronary artery remodeling could be stimulated
by the external application of inflammatory cytokines such as IL-1β and MCP-1 [23,24]. In addition,
EAT potentially can influence the coronary arteries through vasocrine secretion by directly releasing
adipocytokines and free fatty acids (FFA) [5,11,22]. Also, few adipokines such as angiotensinogen, IL-6,
MCP-1, TNF-α, and visfatin secreted by the EAT could cause inflammation, endothelial and smooth
muscle cell proliferation, atherogenesis, and destabilization of atherosclerotic plaque [3]. Adiponectin
is a protein hormone that moderates some of the metabolic processes, including glucose regulation and
fatty acid oxidation [25]. Adiponectin, which has anti-atherogenic and anti-inflammatory properties, is
secreted by EAT in physiological conditions. However, as the EAT becomes hypoxic and dysfunctional
in pathologic conditions, adiponectin secretion is affected [26,27]. Notably, the activity of adiponectin
and the risk of acute myocardial infarction are inversely associated [28].
Leptin, a hormone predominantly made by the adipose cells, is a mediator of long-term regulation
of energy balance, suppressing food intake and thereby inducing weight loss. Leptin secreted by the
EAT inhibits nitric oxide synthetase through protein kinase C dependent mechanisms and thereby
induce endothelial dysfunction [29]. Adrenomedullin (ADR), a peptide hormone with pleiotropic
effects on the vasculature, is significantly associated with EAT in certain disease conditions. Elevated
ADR levels are found in CAD patients which are correlated with endothelial dysfunction [30]. Apart
from this, vitamin D deficiency has been associated with increased expression of inflammatory
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markers in EAT among animal models [31]. However, it is still unknown if this mechanism applies
to humans [32]. Collectively, EAT hypertrophy is observed under various pathological conditions,
and the adipocytokines secreted by the infiltrated immune cells in the EAT could potentially induce
atherosclerotic cardiac disease.
3. Measurement of EAT
Given the widespread availability of non- invasive imaging, EAT measurement has been increasingly
performed in the general population, patients with cardiovascular disease, obesity, and diabetes, as it is a
reliable predictor of cardiovascular risk, independent of traditional risk factors and other fat depots [5].
Echocardiography, computed tomography (CT), or magnetic resonance imaging (MRI) are the three
methods that are used to measure and quantify EAT [5,8]. Various advantages and disadvantages
of these three modalities are given in Table 1 [1,33–39]. Echocardiography is a simple, inexpensive,
and readily available in health care facilities; however, with high intra- and inter-observer variability,
inability to quantify the epicardial fat, and at times overestimation of EAT are some of its significant
drawbacks. Precise measurements of EAT could be made with MRI. Despite MRI being a gold standard
for EAT measurements, in everyday practice, it is hindered by several drawbacks such as high cost,
less availability, and contraindications in patients with pacemakers and implants. Cardiac CT provides
better EAT assessment with the highest specificity and sensitivity. An ability to obtain a coronary
artery calcification (CAC) score with the cardiac CT improves the cardiovascular risk assessment [26].
Cardiac CT involves only a small radiation dose (1 mSv).
Table 1. Salient features of three different EAT measurement modalities.
Advantages Disadvantages
Echocardiography
[1,33–35]
• Widely available, non-invasive, and cost-effective
• Easily repeatable
• Independent from cardiac rhythm;
• Complete and accurate right ventricular function
• No contrast administration and no radiation
• Operator-dependent
• Acoustic window-dependent
• Inconsistency in the measurement location due to
spatial variations
• Observer-dependent
• No volumetric quantification
• Limited to one region (right ventricular free wall)
• Poor image quality (especially in obese individuals)
Computed
Tomography (CT)
[1,34,36–38]
• The 3D technique with short total scan times and
high reproducibility
• Convenient with shorter training time for technicians
• Possibility for volumetric quantification
• Provide image anatomy and function independent
from acoustic window
• Combined assessment of heart, vasculature, and lung
• Better temporal and spatial resolution when compared
to MRI
• Important in patients with contraindications to MRI or
in centers where MRI is not available
• Ionizing radiation risk
• Need for iodinated contrast agent which may affect
renal function in patients with CKD
• Limited information on right ventricular structure
and Function
• Contraindicated in pregnancy
• Limited in separating pericardial/epicardial
adipose tissue
• Weight table limit for severely obese individuals
Magnetic
Resonance
Imaging (MRI)
[1,33,34,36–39]
• The gold standard for adipose tissue imaging
• Non-invasive, safer, 3D imaging with
high reproducibility
• High spatial resolution and very high
temporal resolution
• Ability to depict soft tissues with adequate contrast
• Can be performed with free breathing; Arrhythmias are
generally not a problem
• Can image anatomy, function, and physiology
• Independent from acoustic window
• Possibility for volumetric quantification
• No need for iodinated contrast and no radiation risk
• Expensive and not readily available
• Long total scan times
• Foreign matter causes local artifacts
• Need for long training time
• Several contraindications (e.g., Pacemaker,
arrhythmias, claustrophobia, end-stage renal disease,
implanted metallic devices)
• Provide limited information on lung
• Artifacts including motion, respiratory, cardiac motion
• No accommodation for severely obese individuals
CKD: Chronic kidney disease; MRI: magnetic resonance imaging.
4. Reference Values of EAT
Considering the growing body of evidence indicating the profound role of EAT in the
pathophysiology of CVD, it is imperative to establish the reference ranges of EAT to differentiate or
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identify the population at risk. Furthermore, to establish EAT as a diagnostic marker, defining the
reference ranges becomes a fundamental prerequisite. To this extent, some studies have set forth to
evaluate the EAT thickness in different subject groups. Through the histological analysis of 200 human
hearts, Schejbal has found the mean EAT thickness of the right ventricle (sharp heart edge close to the
bases) as 4.12 mm [40]. Similar observations were made by Flüchter et al. who estimated the mean
right ventricular EAT thickness using cardiac MRI as 4.1 ± 1.1 mm in 28 healthy subjects. In the same
study, the EAT thickness was found to be less (3.2 ± 1.2 mm) in congestive heart failure patients [41].
Of the two analyses carried out on the Framingham Heart MDCT (multi-detector CT) Study
participants, Rosito GA et al. determined the EAT thickness as 110 cm3 and 137 cm3 in men and
women respectively, and Mahabadi AA et al. estimated the mean EAT volume (of the overall subjects
included in the study) as 124 ± 50 cm3 [42,43]. Furthermore, higher EAT thicknesses were observed in
untreated hypertensive patients with grade 1 (impaired relaxation pattern; 7.2 ± 2.4 mm) and grade 2
(pseudo-normal pattern diastolic dysfunction; 7.7 ± 2.3 mm) diastolic dysfunction as compared to
subjects with normal diastolic function (5.4 ± 1.8 mm) [15]. Demir et al. estimated the EAT thickness
of 6.0 ± 2.0 mm in patients with metabolic syndrome as compared to 4.0 ± 1.0 mm in control group
patients (p < 0.001) [44]. In a study involving 950 Indian subjects, EFV was significantly higher in
patients with non-obstructive CAD (68.67 ± 29.18 mL) and obstructive CAD (82.872 ± 32.32 mL) as
compared to subjects with no CAD (56.73 ± 27.63 mL) (p < 0.001) [45].
From the existing evidence, it can be considered that EAT thicknesses > 5 mm, or volume
> 125 mL, or 68 mL/m2 as abnormal [35]. However, an extensive review of the literature with a
systematic approach corroborated with ample clinical experience of the experts from the field is the
need of the hour to establish internationally accepted and reliable reference values for EAT.
5. EAT in Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD)
Chronic kidney disease involves chronic inflammation that is exemplified by the presence of
increased levels of inflammatory markers such as C-reactive protein (CRP), IL-6, and TNF-α in the
circulation [6]. Higher inflammation and oxidative stress are known to play a pivotal role in the
development of atherosclerosis in patients with CKD [6]. A growing body of evidence indicates a
strong association between increased EAT thickness, inflammatory markers, and CAC in patients with
CKD. In a Japanese study on 110 early CKD and 165 non-CKD patients by Nakanishi et al. cardiac CT
scan showed significantly increased EAT volume and vulnerable plaque in CKD patients [46].
Several studies have demonstrated that the EAT thickness is high in hemodialysis or peritoneal
dialysis patients than the healthy subjects (see Table 2 [47–53]). In a study by Sheng et al. n 120 patients
with CKD and 30 healthy subjects, cardiac CT showed higher EAT volume in stage 4–5 D CKD group
patients compared with the control group; however, EAT volume was similar between CKD 3 and
control group [54]. Apart from this, the EFV was significantly higher in the peritoneal dialysis group
than in the hemodialysis group, CAD group compared with no CAD group, and in the diabetes
group than in no diabetes group. Significant research has been dedicated to understanding the
association of EAT thickness in hemodialysis patients with different parameters. In a cross-sectional
study on 43 hemodialysis patients and 30 healthy subjects, the neutrophil-to-lymphocyte ratio (a novel
inflammatory marker) was found to be an independent predictor of EAT in hemodialysis patients [55].
In another cross-sectional study on 72 hemodialysis patients with ESRD, the activity of paraoxonase-1
(PON-1) enzyme has been shown to be inversely correlated with the EAT thickness [56]. PON-1 is the
most potent high-density lipoprotein (HDL) associated antioxidant enzyme whose activity has been
demonstrated to be inversely correlated with oxidative stress and cardiovascular risk [56,57]. Apart
from this, a strong correlation was observed between EAT thickness and ischemiamodified albumin
(IMA) and myeloperoxidase (MPO) in hemodialysis patients; IMA is elevated in ESRD, MPO plays a
role in inflammation and CVD [49]. An inverse correlation between EAT thickness and coenzyme Q10
levels was observed in hemodialysis patients as compared to matched healthy subjects in a study by
Macunluoglu et al. (p < 0.05) [58].
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Table 2. Studies evaluating the EAT thickness in patients on dialysis.
Study Study Population Endpoint Concerning EAT Mode of EATMeasurement EAT Thickness Conclusion
Studies on hemodialysis patients
Altun et al.,
(2014) [47]
62 hemodialysis patients and
40 healthy subjects
Evaluate the relationship
between EAT thickness and
CIMT
Echocardiography
Hemodialysis patients:
6.98 ± 1.67 mm; Healthy
subjects: 3.84 ± 0.73 mm;
p < 0.001
• EAT thickness is higher in hemodialysis patients than in control
subjects and correlated with CIMT, hemodialysis duration, and age.
• CIMT, hemodialysis duration and age are independent predictors of
EAT thickness.
Aydin et al.,
(2017) [48]
60 hemodialysis patients and
84 controls, without diabetes
and CVD; Prospective study
Investigate EAT thickness Transthoracic 2Dechocardiography
Hemodialysis patients:
8.0 ± 2.2 mm; Healthy subjects:
5.8 ± 1.9 mm; p < 0.01
• Hemodialysis patients have significantly higher EAT thickness.
• Hemodialysis patient status is an independent predictor of
EAT thickness.
Karatas et al.,
(2018) [49]
37 hemodialysis patients,
43 pre-dialysis patients,
31 healthy subjects
Examine the relationship of EAT
thickness with IMA and MPO
levels in patients with CKD
Transthoracic
echocardiography
Hemodialysis patients:
6.841 ± 1.194 cm; pre-dialysis
patients: 6.261 ± 1.302 cm;
healthy subjects:
4.053 ± 0.611 cm; p < 0.001.
• EAT is significantly high in the hemodialysis group as compared to
pre-dialysis and healthy subjects.
• IMA and MPO levels are significantly high in hemodialysis subjects.
• EAT thickness positively correlates with IMA and MPO levels
Studies on peritoneal dialysis patients
Turkmen et al.,
(2012) [50]
45 Peritoneal dialysis patients,
25 healthy subjects;
Cross-sectional study
Investigate the relationship
between EAT and CAC in
peritoneal dialysis patients
MDCT
Peritoneal dialysis patients:
160 ± 77 cm3; Healthy subjects:
121.5 ± 37.5 cm3; p = 0.02
• EAT thickness is high in peritoneal dialysis patients.
• EAT measurements significantly correlates with arterial calcification
of the main segments of the coronary artery.
• Patients with BMI ≥ 30 has increased EAT than those with BMI < 30.
• Increased EAT positively correlated with age and BMI.
Turkmen et al.,
(2013) [51]
35 Peritoneal dialysis patients,
30 healthy subjects;
Cross-sectional study
Evaluate PFT thickness and
independent predictors of PFT in
peritoneal dialysis patients
MDCT
Peritoneal dialysis patients:
170 ± 79 cm3; Healthy subjects:
120 ± 43 cm3; p = 0.003 • PFT is strongly correlated with EAT in peritoneal dialysis patients.
Studies involving both hemodialysis and peritoneal dialysis patients
Turkmen et al.,
(2011) [52]
80 ESRD patients either on
hemodialysis or peritoneal
dialysis, 27 healthy subjects;
Cross-sectional study
Investigate the relationship
between EAT and MIAC
syndrome
MDCT
ESRD patients: 160 ± 76 cm3;
Healthy subjects:
121.5 ± 37.5 cm3; p = 0.02
• Increased EAT in ESRD patients as compared to healthy subjects.
• EAT measurements were higher in peritoneal dialysis patients than
in hemodialysis patients
• EAT significantly correlated with MIAC syndrome in ESRD patients
• EAT significantly increased upon an increase in a number of
MIAC components.
• EAT is positively correlated with age, BMI, and MIAC.
Erdur et al.,
(2013) [53]
76 ESRD patients receiving
peritoneal- or hemodialysis
and 42 healthy subjects;
Cross-sectional study
Determine the relationship
between AIP and EAT MDCT
ESRD patients: 160 ± 76 cm3;
Healthy subjects: 104 ± 48 cm3;
p < 0.001
• Compared to healthy subjects, AIP and EAT are increased in
ESRD patients.
• Significant correlation between EAT and BMI and AIP in
ESRD patients.
• AIP is significantly high in ESRD patients with high EAT volumes.
• Age and BMI are independent predictors of EAT.
AIP, atherogenic index of plasma; BMI, body mass index; CAC, coronary artery calcification; CIMT, carotid intima-media thickness; CVD, cardiovascular disease; EAT, epicardial adipose
tissue; ESRD, end-stage renal disease; IMA, ischemia-modified albumin; MIAC, malnutrition, inflammation, atherosclerosis, calcification; MDCT, multi-detector computed tomography;
MPO, myeloperoxidase; PFT, peri-aortic fat tissue.
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6. EAT in Renal Transplantation
Limited literature is available on the EAT in kidney transplant patients. In a post hoc analysis on
98 kidney transplant patients, the impact of the epicardial fat gain on ventricular mass after kidney
transplantation could not be positively confirmed [59]. Similar to hemodialysis patients, PON-1
activity was found to be inversely correlated with EAT thickness in renal transplant patients [60].
When EAT changes were compared between hemodialysis patients and kidney transplant patients,
EAT measurements were significantly higher in hemodialysis patients than in the kidney transplant
patients, and the EAT measurements of the kidney transplant patients were not statistically different
from the healthy subjects [61]. This suggests that kidney transplantation could reduce EAT as the
kidney transplant patients in this study were previously on hemodialysis.
7. Microalbuminuria and EAT
Studies demonstrated higher EFV in microalbuminuria patients. In a study on essential
hypertensive patients, mean EAT thickness was higher in those with microalbuminuria as compared to
the normoalbuminuric patients with significant positive correlations between EAT and LV mass and LV
mass index [62]. Akbas et al. made similar observations in type 2 diabetes patients where EAT thickness
was significantly high in macro- albuminuric or micro-albuminuric patients than normoalbuminuric
patients [63]. Furthermore, EAT was identified as an independent predictor of increased albuminuria
in this study. Likewise larger EAT volumes were observed in type 1 diabetes patients with a history of
an albumin excretion rate ≥300 mg/dL [64].
8. EAT and Coronary Artery Calcification in Renal Disease
Cardiovascular diseases are the most common cause of morbidity and mortality in CKD
patients [65]. CAC indicates the presence of coronary atherosclerosis [66], and it usually correlates
with increased cardiovascular risk and poor outcomes mainly in patients with CKD [67–70]. EAT
measurement is generally used to confirm the association with CAC; it characterizes the presence
of high-risk coronary artery plaque [69,71]. It is notable that the volume of EAT is eligible as a
marker of coronary atherosclerosis even with a coronary artery calcium score of zero on coronary
CT angiography [72]. In a large meta-analysis by Nerlekar et al., increased EAT and the presence of
high-risk plaque are significantly correlated [73]. In the prospective EVASCAN (EVAluation of CT
SCANner) study that investigated the association of EAT thickness with the extent of angiographic
CAD, EAT thickness of left ventricle wall was associated with CAD and was identified as an
independent predictor of CAD [74]. In the Cardiometabolic risk, Epicardial fat, and Subclinical
Atherosclerosis Registry (CAESAR) study participants, increase in EAT and the extent of calcium in
the coronary artery are significantly correlated [75]. In a study on the normotensive patients with
autosomal dominant polycystic kidney disease (ADPKD), EAT thickness, and carotid intima-media
thickness (CIMT) was higher than the control subjects [76], In addition, a statistically significant
positive association was observed between EAT thickness and CIMT [76]. A robust association was
observed between CAC and EFV in pre-dialysis stage 3–4 CKD patients, and the EFV is greater in
individuals with metabolic syndrome, increased insulin resistance, or diabetes mellitus [77]. Through
a retrospective analysis on 529 patients with high risk of coronary atherosclerotic nephropathy, Zuo
et al. have identified higher EAT thickness in patients with atherosclerosis [78]. The authors suggest
that measuring EAT volume could predict the occurrence and development of coronary atherosclerosis
in the future [78]. The study also found a positive correlation between EAT volume and coronary
artery calcification, BMI and number of coronary lesions in patients with nephropathy [78].
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When the EAT and CAC score was investigated in diabetic, nondiabetic ESRD patients,
and healthy subjects, total CAC scores and EAT measurements were significantly higher in diabetic
ESRD patients [79]. A statistically significant relationship was observed between EAT and CAC scores
in ESRD patients (p < 0.0001) [79]. Furthermore, statistically significant higher EAT measurements were
observed in both diabetic and non-diabetic ESRD patients when compared to healthy subjects (p < 0.01
for healthy subjects vs. ESRD patients). In a study that investigated the relationship between EAT and
surrogate cardiovascular markers in patients on maintenance hemodialysis, EFV was significantly
higher in patients with higher CAC scores (>10), and it correlated with atherosclerosis, arterial stiffness,
and the presence of CAC [80]. However, in a study of 93 patients on long-term hemodialysis, save for
the subjects younger than 55 years of age, the EFV was not significantly correlated to the CAC [81].
Taken together, information from most of the studies suggest a strong correlation between EAT
thickness and CAC in renal disease patients.
9. Clinical Significance of EAT in Renal Disease
In CKD patients, EAT assessment could be a reliable parameter for cardiovascular risk
assessment [69]. Inflammation in CKD patients is remarkable when compared to the general population
as malnutrition adds onto the already existing high inflammatory state of these patients; as a result,
inflammation caused by adipose tissue is more relevant in CKD patients [52,69]. Despite some
limitations, the study by Cordeiro et al. provides valuable insights into the association between
EAT and CVD risk factors and CV events in CKD patients [82]. In this single-center, cross-sectional,
prospective observational study on 227 non-dialyzed stage 3–5 CKD patients, an increase in EAT
thickness was associated with severity of CVD; as the EAT thickness increased, the high prevalence of
LV hypertrophy and myocardial ischemia was observed along with high CAC score. Furthermore,
elevated EAT thickness was associated with poor CVD prognosis. Another important observation
from this study is that higher EAT was associated with an increased risk of cardiovascular events
independently of visceral (abdominal) fat and other potential confounders [82]. Notably, the authors
indicate that EAT does not add any meaningful prognostic power beyond visceral fat and CKD related
risk factors. Apart from this, in a 6.1 year follow-up, prospective study on 200 type 2 diabetes patients
with elevated urinary albumin excretion rate, EAT was significantly (p = 0.029) associated with CVD
and mortality even after accounting for traditional CVD risk factors [83]. Moreover, it is suggested
that EAT is not a cardiovascular risk indicator in hemodialysis patients without diabetes mellitus and
hypertension [84]. However, in a study on 177 outpatients at intermediate risk for CAD, EAT volume
was suggested to provide incremental predictive value for future cardiac events [85]. Likewise, in a
study by Reinhardt et al., in individuals with early adult onset T2DM, EFV was suggested as a risk
factor for heart disease, and in individuals with youth-onset T2DM, it is indicated as a predictor of
decreased kidney function [86]. Authors of the study commented that, while EFV might influence renal
disease in youth, and renal disease is a precursor to macrovascular disease, it is more likely that EFV is
a marker of metabolic syndrome predisposing to both conditions [86]. Metabolic syndrome is linked
to epicardial fat storage and EAT might just be a marker of metabolic syndrome or exacerbate the risk
of metabolic syndrome on kidney disease [86]. Collectively, it seems that EAT has a prominent role in
precipitating CVD events, and these observations deserve thorough examination and consideration in
clinical practice, and must be extensively studied further through high-quality clinical studies.
In a post-hoc analysis of a prospective study on 59 hemodialysis patients, EAT correlated
significantly with cardiovascular calcification in long-term HD patients [87]. In addition, EAT
correlated significantly with age, BMI, CAC, and aortic calcium. In the post-hoc analysis of the
Renagel in New Dialysis patients (RIND study) each 10 cm3 increase in EAT volume in hemodialysis
patients was associated with a significant 6% increase in the risk of death during follow-up [88]. Age,
BMI, CAC, and aortic calcium were also found to be positively correlated with EAT in the study.
In another subgroup analysis of RIND study participants EAT progression from baseline was smaller
in hemodialysis patients treated with sevelamer (calcium-free phosphate binder) than in patients
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treated with the calcium-containing phosphate binder [89]. In a study that investigated the relationship
between EAT and MIAC (malnutrition, inflammation, atherosclerosis/calcification) syndrome in
ESRD patients, total CAC score and EAT measurement were higher, EAT positively correlated with
CAC score, age and BMI, and EAT was increased when MIAC components increased [52]. Overall
evidence indicates that age, BMI, CIMT, CAC, and hemodialysis status as some of the factors to
have a positive correlation with EAT thickness in renal disease patients and hence these factors deem
specific consideration during the treatment. As considerable evidence indicates EAT as an independent
predictor of CVD and mortality in renal disease patients, it is rational to acknowledge the importance
of therapeutic interventions to reduce EAT.
10. Clinical Reduction of EAT
Strategies to decrease EAT comprise simple lifestyle modifications including diet control and
exercise to medical therapy and even more complex surgical interventions. In a prospective study on
30 non-diabetic obese men with metabolic syndrome, a 3-month weight reduction plan, including diet
control and exercise, resulted in a statistically significant (p < 0.001) reduction in EAT thickness ranging
from −34% to −18% (as per measurements in various planes) in men who had >5% weight loss [90].
Interestingly, the decrement in EAT thickness correlated with improvement in insulin sensitivity index
in these subjects. Likewise, in another study on 20 severely obese subjects (BMI 45 ± 5 kg/m2),
a 6 month very low-calorie diet program resulted in 20% loss of bodyweight, 19% loss of BMI and
importantly 32% loss of EAT (p < 0.001), as compared to baseline [91]. With weight loss, significant
improvements in left ventricular mass (LVM) and diastolic function were also observed in these
patients which correlated better with EAT loss rather than BMI or waist circumference reduction.
Concerning medications, statins, and different anti-diabetes medications have been shown to
reduce EAT significantly in various studies (see Table 3 for details [92–100]). Independent of the
effects on blood cholesterol or lipoproteins, high doses of statins both lower the EAT thickness
and its pro-inflammatory characteristics, and thus reduce systemic inflammation [2]. In a study on
193 patients with aortic stenosis undergoing cardiac surgery, statin treatment was associated with
significantly lower EAT thickness (p < 0.0001) and lower levels of EAT-secreted inflammatory mediators
(p < 0.0001) [101]. Moreover, the study also identifies a significant correlation between EAT thickness
and its inflammatory status.
Different classes of anti-diabetic drugs such as sodium glucose co-transporter-2 inhibitors
(SGLT2i), glucagon-like peptide-1 receptor agonist (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors
(DPP-4i), have been shown to reduce the EAT thickness to a varying extent; see Table 3 for the details
of the observations in various studies. The EAT reduction effect of these anti-diabetic drugs could
probably be due to their impact on reducing the body weight or in some cases specifically the body
fat. In a study on EAT explants, dapagliflozin, a SGLT2 i have been shown to reduce the secretion of
pro-inflammatory chemokines and improve the differentiation of EAT cells [102]. When the expression
of pro-inflammatory markers was quantified in EAT of CAD patients with type 2 diabetes who had
undergone surgery, pioglitazone, a thiazolidinedione drug, significantly reduced the expression of
IL-1β, IL-1Ra, and IL-10 [103]. In a study on 73 multi-vessel CAD patients who underwent elective
bypass grafting, a combination of simvastatin (20 mg/day) and pioglitazone (15 mg or 30 mg/day)
substantially reduced EAT and plasma inflammatory markers in CAD and metabolic syndrome
patients [104].
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Table 3. Evidence indicating the reduction of EAT with pharmacological intervention.
Study Study Population; Study Duration Pharmacological Therapy and Dose Results Conclusion
Statins
Alexopoulos
et al., (2013) [92] 420 post-menopausal women; One year
A: Atorvastatin 80 mg/day B:
Pravastatin 40 mg/day
% change in EAT. A versus B*: −3.38 (−30.1
to 40.1) vs. −0.83 (−37.9 to 62.8); p = 0.025 • Intensive lipid-lowering therapy with atorvastatin significantlyreduces EAT volume.
Soucek et al.,
(2015) [93]
79 patients with AF who underwent
pulmonary vein isolation; 3 months A: Atorvastatin 80 mg/day B: Placebo
Median decrease in EAT volume (baseline vs.
follow-up) *: A: 92.3 cm3 (62.0 to 133.3) vs
86.9 cm3 (64.1 to 124.8); p < 0.05.
B: 81.9 cm3 (55.5 to 110.9) vs 81.3 cm3 (57.1 to
110.5), p = NS.
• Intensive atorvastatin therapy in AF patients who underwent
pulmonary vein isolation significantly decreases EAT thickness.
Anti-diabetes medications
SGLT2i
Bouchi et al.,
(2017) [94] 19 T2D patients; 12 weeks
Luseogliflozin 2.5 mg daily, titrated up
to 5 mg daily
Median decrease in EAT volume (baseline vs.
follow-up) *: 117 cm3 (96–136) vs. 111 cm3
(88–134); p = 0.048
• Luseogliflozin significantly reduces EFV in T2D patients.
• EFV reduction significantly correlates with C-reactive
protein reduction.
Fukuda et al.,
(2017) [95] 9 non-obese T2D patients; 12 weeks Ipragliflozin 50 mg daily
Median decrease in EAT volume (baseline vs.
follow-up) *: 102 (79–126) cm3 vs. 89
(66–109) cm3; p = 0.008
• Ipragliflozin significantly reduces EFV in non-obese
T2D patients.
• EFV reduction significantly correlates with change in BMI.
Sato et al., (2018)
[96] 40 T2D patients with CAD; 6 months
A: Dapagliflozin B: Conventional
treatment involving various
anti-diabetes drugs
Reduction in EAT volume (A vs. B):
−16.4 ± 8.3 cm3 vs. 4.7 ± 8.8 cm3; p = 0.01
• Dapagliflozin reduces EAT volume significantly.
• The significant correlation observed between changes in EAT
volume and the difference in body weight or TNF-α level.
Yagi et al., (2017)
[97] 13 T2D patients; 6 months Canagliflozin 100 mg
The decrease in EAT thickness (baseline vs.
follow-up): 9.3 ± 2.5 vs. 7.3 ± 2.0 mm;
p < 0.001
• Canagliflozin reduces EAT thickness in T2D patients
independent of its effect on blood glucose.
GLP-1 Analogues
Dutour et al.,
(2016) [98]
44 obese T2D subjects uncontrolled on
oral antidiabetic drugs; 26 weeks
A: Exenatide 5 µg to 10 µg b. i. d. B:
Reference treatment
Reduction in EAT: A: −8.8 ± 2.1%;
B: −1.2 ± 1.6%; p = 0.003
• Exenatide significantly reduces EAT in obese T2D patients
• These effects mainly depend on weight loss
Iacobellis et al.,
(2017) [99]
95 T2D patients with BMI ≥ 27 kg/m2
and A1C ≤ 8%; 6 months
A: Liraglutide up to 1.8 mg s.c.
o. d. + Metformin up to 1000 mg b. i. d.
B: Metformin up to 1000 mg b. i. d.
Reduction in EAT (baseline vs. follow-up):
A: 9.6 ± 2 mm vs. 6.2 ± 1.5 mm; p < 0.001
B: 7.4 ± 1.6 mm vs. 6.9 ± 1.3 mm; p = NS
• Liraglutide added to metformin results in about 36% reduction
of EAT
DPP-4i
Lima-Martinez
et al., (2106) [100]
26 T2D patients with A1C ≥ 7%;
24 weeks
A: Sitagliptin 50 mg + Metformin
1000 mg b. i. d.
Reduction in EAT (baseline vs. follow-up):
A: 9.98 ± 2.63 vs. 8.10 ± 2.11 mm; p = 0.001 • Addition of sitagliptin to metformin reduces the EATsignificantly and rapidly
A1C, glycated hemoglobin; AF, atrial fibrillation; b. i. d., twice daily; BMI, body mass index; DPP-4i, dipeptidyl peptidase-4 inhibitors; EAT, epicardial adipose tissue; EFV, epicardial fat
volume; GLP-1RAs, glucagon-like peptide-1 receptor agonists; o. d., once daily; NS, statistically not significant; s. c., sub-cutaneous; SGLT2i, sodium glucose co-transporter-2 inhibitors;
T2D, type 2 diabetes mellitus; TNF, tumor necrosis factor; *, values represent median (range).
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Owing to the high sensitivity of renal disease patients to different medications, therapeutic
interventions should be carefully chosen to reduce EAT thickness. The 2013 Kidney Disease: Improving
Global Outcomes (KDIGO) Clinical Practice Guideline for Lipid Management in Chronic Kidney
Disease recommend that statins can be used in adults aged≥50 years with eGFR≤ 60 mL/min/1.73 m2
but not treated with chronic dialysis or kidney transplantation, in adults aged ≥50 years with CKD
and eGFR ≥ 60 mL/min/1.73 m2, in adults aged 18–49 years with CKD, but not treated with chronic
dialysis or kidney transplantation, and in adult kidney transplant recipients [105]. In adults with
dialysis-dependent CKD, the statins are contraindicated; however, statin treatment can be continued
if a patient is already receiving statins or statin/ezetimibe combination at the time of dialysis
initiation [105]. Special care should be taken while prescribing any of the anti-diabetic drugs in
the CKD patients as the American Diabetes Association (ADA) recommends either dose modifications
or in some cases contraindicate these drugs [106]. The ADA guidelines do not recommend canagliflozin
and dapagliflozin when the eGFR is less than 45 mL/min/1.73 m2 and 60 mL/min/1.73 m2 respectively,
and contraindicate dapagliflozin in patients with eGFR < 45 mL/min/1.73 m2 [106]. The 2012 update of
the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline for Diabetes and
Chronic Kidney Disease do not suggest any dosage adjustment for pioglitazone [107]. For sitagliptin,
the KDOQI guidelines recommend a dose of 100 mg daily when eGFR > 50 mL/min/1.73 m2, 50 mg
daily when eGFR is 30–50 mL/min/1.73 m2 and 25 mg daily when eGFR < 30 mL/min/1.73 m2 [107].
Regarding the GLP-1RAs, the KDOQI guidelines do not recommend exenatide and liraglutide when
eGFR < 30 mL/min/1.73 m2 and <60 mL/min/1.73 m2 respectively [107].
Surgical interventions involving bariatric surgery or direct surgical resection of EAT have been
shown to reduce EAT. In a study on morbidly obese patients, six months after bariatric surgery,
epicardial fat volume reduced from 137 ± 37 mL to 98 ± 25 mL (p < 0.0001), along with a substantial
reduction in BMI, subcutaneous fat, and visceral abdominal fat [108]. In the case of epicardial
hypertrophy, surgical resection has been shown to reduce the EAT and thereby improve cardiac
function [109]. Taken together, strategies to reduce EAT thickness should initiate with lifestyle
modifications followed with therapeutic intervention. Surgical procedures could be considered as the
last option for EAT reduction.
11. Conclusions
It has been well established that EAT plays a multifaceted role in cardiac metabolism and its
importance in regulating cardiac disease pathogenesis is being accepted widely. Notably, due to its
anatomic proximity to the myocardium, EAT is gaining immense attention as inflammatory molecules
secreted by EAT could have a paracrine and vasocrine effect on the myocardium. As the EAT thickness
could increase before the mature atherosclerotic plaque development, EAT assessment may be useful
in screening and initiating treatment during the earlier stages of CVD. Also, EAT could cause coronary
artery calcification and may predict its progression, which ultimately results in myocardial ischemia.
Even though CVD poses a significant risk in ESRD patients (mortality rate due to cardiovascular
events is high in ESRD patients), they are often asymptomatic due to diabetes or impaired exercise
capacity [110]. Traditional screening tools lack predictive accuracy in identifying these symptoms in
ESRD patients due to a variety of reasons emanating from their clinical staus [110]. Therefore, there is
a quintessential need for identifying risk factor(s) or marker(s) through which future cardiac events
could be diagnosed, and the patient could be provided with proper care at the right time. To this extent,
we propose that measuring the EAT volume could be a marker for cardiovascular risk stratification
in ESRD patients. At this point, we accede that there is a significant dearth of evidence both at the
level of animal studies or on humans which strengthen our assumption. However, considerable body
of current evidence indicat that CKD and ESRD patients have higher EAT volume motivates to test
this hypothesis. Furthermore, to our knowledge, the cause-effect relationship between EAT volume,
cardiovascular risk, and renal disease has not been established. Therefore, it also remains a fertile area
for future research.
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Also, future large scale trials are required to assess the prognostic significance of reducing
the EAT thickness in different patient groups and especially in patients with renal disease. As a
positive correlation between EAT thickness and age, BMI, CIMT, CAC and hemodialysis status has
been consistently observed in renal disease patients in many independent studies, these factors
could be given importance in the clinical practice. Data suggest that EAT thickness can be reduced
non-pharmacologically with lifestyle modifications including low-calorie diet and anaerobic exercise.
Even though low-quality studies indicate that different pharmacological interventions (mainly statins
and some anti-diabetes drugs) can reduce the EAT thickness, high quality randomized, double-blind
trials are required to ascertain these effects. Overall, epicardial adipose tissue could be a reliable
cardiovascular clinical parameter in both CKD and non-CKD subjects that can be readily measured by
non-invasive, cheap and reliable methods to stratify the patients and design the management plan.
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